Custom Compounded Therapy Market Report 2026

The custom compounded therapy market size has grown strongly in recent years. It will grow from $5.96 billion in 2025 to $6.42 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, unmet needs in standardized drug therapies, expansion of specialty pharmacy services, growing geriatric population demand, rising physician preference for customized treatments.

The custom compounded therapy market size is expected to see strong growth in the next few years. It will grow to $8.56 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for allergen-free formulations, expansion of home-based care models, growing regulatory clarity for compounding practices, increasing patient-centric healthcare delivery. Major trends in the forecast period include increasing adoption of personalized medication formulations, growing demand for patient-specific dosage customization, expansion of specialty compounding pharmacies, rising use of advanced compounding technologies, enhanced focus on treatment adherence.

The increasing demand for personalized medications is expected to drive growth in the custom compounded therapy market in the coming years. Personalized medication involves tailoring medical treatments to the individual characteristics, needs, and preferences of each patient, often considering genetic, clinical, and lifestyle factors. This approach is gaining popularity because it improves treatment effectiveness and minimizes adverse drug reactions by aligning therapies with individual patient profiles. Custom compounded therapy supports this personalization by producing formulations that match each patient’s specific requirements, including precise doses, combinations, and delivery methods, ensuring better outcomes. For example, in 2023, the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases, up from six in 2022, highlighting the rising demand for individualized therapies. Consequently, this trend is fueling growth in the custom compounded therapy market.

Leading companies in the custom compounded therapy market are focusing on developing innovative solutions, such as advanced compounding software, to address the growing need for precise, efficient, and personalized medication preparation. Compounding software streamlines the formulation process by integrating digital automation, quality control, and real-time data tracking, providing a more reliable and scalable alternative to traditional manual methods. For instance, in October 2025, CurifyLabs, a Finland-based health technology company, launched its Next-Generation Compounding Software, an advanced platform designed to enhance accuracy and efficiency in personalized medicine. The system supports automated formulation design, integrates with smart compounding devices, and incorporates quality safeguards to reduce human error. It allows pharmacies and healthcare facilities to produce customized therapies more consistently, improves traceability through digital documentation, and speeds up preparation times. By offering a fully digital compounding workflow, this solution significantly advances the capabilities of custom compounded therapy and enables safer, more individualized patient care.

In April 2024, Myonex, Inc., a U.S.-based clinical trial supply company, acquired SaveWay Compounding Pharmacy, Inc. for an undisclosed amount. This acquisition enables Myonex to expand its clinical trial services across the U.S. by leveraging SaveWay Compounding Pharmacy’s expertise in custom-compounded medications. It strengthens Myonex’s ability to deliver personalized drug formulations and ensures reliable access to tailored therapies for both patients and clinical research. SaveWay Compounding Pharmacy specializes in producing personalized sterile and non-sterile medications, supporting the growing demand for individualized therapies.

Major companies operating in the custom compounded therapy market are Hikma Pharmaceuticals PLC, Fagron N.V., Nephron Pharmaceuticals Corporation, Belmar Pharmacy LLC, Empower Clinic Services LLC, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Wedgewood Connect LLC, AnazaoHealth Corporation, Wells Pharmacy Network LLC, Institutional Pharmacy Solutions Inc., Bennett Pharmaceuticals of America LLC, Bravado Pharmaceuticals LLC, Pencol Compounding Pharmacy Inc., Rx3 Compounding Pharmacy Inc., CareFirst Specialty Pharmacy LLC, Vertisis Custom Pharmacy LLC, FarmaKeio Pharmacy Network LLC, Professional Compounding Centers of America, Letco Medical LLC.

North America was the largest region in the custom compounded therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the custom compounded therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the custom compounded therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the custom compounded therapy market by increasing costs of imported active pharmaceutical ingredients, excipients, compounding equipment, and specialized packaging materials. Hospitals, specialty pharmacies, and clinics in North America and Europe are most affected due to reliance on global ingredient sourcing, while Asia-Pacific faces supply cost volatility for raw materials. These tariffs are raising formulation costs and pricing pressure for personalized therapies. However, they are also encouraging domestic API production, local sourcing strategies, and investment in in-house compounding capabilities, supporting long-term supply resilience.

The custom compounded therapy market research report is one of a series of new reports that provides custom compounded therapy market statistics, including custom compounded therapy industry global market size, regional shares, competitors with a custom compounded therapy market share, detailed custom compounded therapy market segments, market trends and opportunities, and any further data you may need to thrive in the custom compounded therapy industry. This custom compounded therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Custom compounded therapy involves the preparation of personalized medications by pharmacists, designed to address the specific needs of individual patients when standard treatments are unsuitable. Its aim is to offer customized dosages, formulations, or ingredients to enhance treatment effectiveness, safety, and patient adherence.

The primary product types of custom compounded therapy include hormone replacement therapy, pain management, dermatology, nutritional supplements, and others. Hormone replacement therapy is a medical treatment that restores or supplements hormones in the body to alleviate symptoms caused by hormone deficiencies or imbalances. These therapies are offered in various forms, such as intravenous (IV) therapy, topical therapy, oral therapy, and subcutaneous therapy, with different formulations including injectable, oral, and transdermal. They are applied across multiple therapeutic areas, including oncology, neurology, cardiology, endocrinology, and pain management, with major end-users being hospitals, clinics, homecare settings, and specialty pharmacies.

The custom compounded therapy market consists of revenues earned by entities by providing services such as compounding pharmacy services, personalized consultations, prescription customization, and ongoing patient care support. The market value includes the value of related goods sold by the service provider or included within the service offering. The custom compounded therapy market also includes sales of topical creams, gels, sterile injectables, transdermal patches, and veterinary compounded medications. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.